Elis Pharmaceuticals will present erectile dysfunction drug Vitaros licensed from Apricus Biosciences at the Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT), as part of its pre-launch strategy.
Elis Pharmaceuticals received the license for Vitaros from Apricus Biosciences in January of 2011, having exclusive rights to sell the drug in the Gulf Countries and part of the Middle East. Elis chief executive officer Rashed Assouma said the company believes that Vitaros will be an important new first line therapy for ED in this region.
“Since DUPHAT is the most significant pharmaceutical event in the Middle East and North Africa, it offers the best opportunity for us to introduce the drug,” Assouma said. Health Canada approved Vitaros in November 2010 as the first topical treatment for erectile dysfunction for marketing in Canada.
